Technology Bundle ID
NCI-E-025-2006

Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use

Applications
Therapeutics
Lead Inventors
Barry OKeefe (NCI)
Co-Inventors
James McMahon ()
Toshiyuki Mori (NCI)
Development Status
Discovery (Lead Identification)
ICs
NCI

This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).  Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection. 

Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted)

Commercial Applications
  • Microbicide that can prevent viral transmission
  • Therapeutic against enveloped virus-mediated diseases 
Competitive Advantages
  • Highly Potent Broad-Spectrum Antiviral Lectin
  • Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.

Request More Info

Licensing Contact:
Taryn Dick
taryn.dick@nih.gov

Intellectual Properties

  • Pat 8,088,729

    Issued 2012-01-03

Publications

  • Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture
    PMID: 16300962
  • Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
    PMID 15613479

Collaborations

Collaboration Description

  • Licensing and research collaboration
Date Published